These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 30611836)

  • 1. Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review.
    Cao B; Zhu J; Zuckerman H; Rosenblat JD; Brietzke E; Pan Z; Subramanieapillai M; Park C; Lee Y; McIntyre RS
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():109-117. PubMed ID: 30611836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anhedonia among patients with Major Depressive Disorder: A comparison between patients on escitalopram and healthy controls.
    Ng CG; Wong SK; Loh HS; Yee A
    Clin Ter; 2014; 165(6):e384-90. PubMed ID: 25524191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anhedonia and major depression: the role of agomelatine.
    Di Giannantonio M; Martinotti G
    Eur Neuropsychopharmacol; 2012; 22 Suppl 3():S505-10. PubMed ID: 22959116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials.
    Tedeschini E; Levkovitz Y; Iovieno N; Ameral VE; Nelson JC; Papakostas GI
    J Clin Psychiatry; 2011 Dec; 72(12):1660-8. PubMed ID: 22244025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in "real-world," everyday clinical practice.
    De Berardis D; Fornaro M; Orsolini L; Iasevoli F; Tomasetti C; de Bartolomeis A; Serroni N; De Lauretis I; Girinelli G; Mazza M; Valchera A; Carano A; Vellante F; Matarazzo I; Perna G; Martinotti G; Di Giannantonio M
    CNS Spectr; 2017 Aug; 22(4):342-347. PubMed ID: 27702411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of antidepressants on measures of workplace functioning in major depressive disorder: A systematic review.
    Lee Y; Rosenblat JD; Lee J; Carmona NE; Subramaniapillai M; Shekotikhina M; Mansur RB; Brietzke E; Lee JH; Ho RC; Yim SJ; McIntyre RS
    J Affect Disord; 2018 Feb; 227():406-415. PubMed ID: 29154157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The promise of ketamine for treatment-resistant depression: current evidence and future directions.
    DeWilde KE; Levitch CF; Murrough JW; Mathew SJ; Iosifescu DV
    Ann N Y Acad Sci; 2015 May; 1345(1):47-58. PubMed ID: 25649308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis.
    Oliva V; Lippi M; Paci R; Del Fabro L; Delvecchio G; Brambilla P; De Ronchi D; Fanelli G; Serretti A
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jul; 109():110266. PubMed ID: 33549697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy, acceptability, and safety of medicinal, cognitive-behavioral therapy, and placebo treatments for acute major depressive disorder in children and adolescents: a multiple-treatments meta-analysis.
    Ma D; Zhang Z; Zhang X; Li L
    Curr Med Res Opin; 2014 Jun; 30(6):971-95. PubMed ID: 24188102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine.
    Lally N; Nugent AC; Luckenbaugh DA; Niciu MJ; Roiser JP; Zarate CA
    J Psychopharmacol; 2015 May; 29(5):596-607. PubMed ID: 25691504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indices of Change, Expectations, and Popularity of Biological Treatments for Major Depressive Disorder between 1988 and 2017: A Scientometric Analysis.
    Tran BX; Ha GH; Vu GT; Nguyen LH; Latkin CA; Nathan K; McIntyre RS; Ho CS; Tam WW; Ho RC
    Int J Environ Res Public Health; 2019 Jun; 16(13):. PubMed ID: 31247926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
    Cipriani A; Zhou X; Del Giovane C; Hetrick SE; Qin B; Whittington C; Coghill D; Zhang Y; Hazell P; Leucht S; Cuijpers P; Pu J; Cohen D; Ravindran AV; Liu Y; Michael KD; Yang L; Liu L; Xie P
    Lancet; 2016 Aug; 388(10047):881-90. PubMed ID: 27289172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of anhedonia on health-related quality of life and functional outcomes in major depressive disorder: A systematic review and meta-analysis.
    Wong S; Le GH; Phan L; Rhee TG; Ho R; Meshkat S; Teopiz KM; Kwan ATH; Mansur RB; Rosenblat JD; McIntyre RS
    J Affect Disord; 2024 Jul; 356():684-698. PubMed ID: 38657767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.
    Khoo AL; Zhou HJ; Teng M; Lin L; Zhao YJ; Soh LB; Mok YM; Lim BP; Gwee KP
    CNS Drugs; 2015 Aug; 29(8):695-712. PubMed ID: 26293743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High efficiency of left superior frontal gyrus and the symptom features of major depressive disorder.
    Zhang L; Li Z; Lu X; Liu J; Ju Y; Dong Q; Sun J; Wang M; Liu B; Long J; Zhang Y; Xu Q; Li W; Liu X; Guo H; Lu G; Li L
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Mar; 47(3):289-300. PubMed ID: 35545321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anhedonia predicts poor psychosocial functioning: Results from a large cohort of patients treated for major depressive disorder by general practitioners.
    Vinckier F; Gourion D; Mouchabac S
    Eur Psychiatry; 2017 Jul; 44():1-8. PubMed ID: 28535406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
    Rodrigues NB; McIntyre RS; Lipsitz O; Cha DS; Lee Y; Gill H; Majeed A; Phan L; Nasri F; Ho R; Lin K; Subramaniapillai M; Kratiuk K; Mansur RB; Rosenblat JD
    J Affect Disord; 2020 Nov; 276():570-575. PubMed ID: 32871688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological Treatments for Anhedonia.
    Klein ME; Grice AB; Sheth S; Go M; Murrough JW
    Curr Top Behav Neurosci; 2022; 58():467-489. PubMed ID: 35507281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials.
    Majeed A; Xiong J; Teopiz KM; Ng J; Ho R; Rosenblat JD; Phan L; Cao B; McIntyre RS
    Expert Opin Emerg Drugs; 2021 Mar; 26(1):63-74. PubMed ID: 33682569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of levomilnacipran ER across symptoms of major depressive disorder: a post hoc analysis of 5 randomized, double-blind, placebo-controlled trials.
    McIntyre RS; Gommoll C; Chen C; Ruth A
    CNS Spectr; 2016 Oct; 21(5):385-392. PubMed ID: 27292817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.